Treviso, November 10, 2025 – SolidWorld Group S.p.A., listed on Euronext Growth Milan (ticker: S3D), is an Italian technology group, leader in the integration of advanced 3D digital solutions and artificial intelligence, for the industrial, biomedical and defense sectors, marks a new step forward in the development of regenerative medicine.
Thanks to Electrospider, the first Italian 3D bioprinter patented worldwide and developed by Bio3DPrinting, a company controlled by Bio3DModel and part of the SolidWorld Group, a proof of concept of a biomimetic tracheal scaffold has been created, capable of reproducing the topological complexity of human tissue and opening new perspectives for research applied to organ regeneration.
This study represents a concrete example of collaboration between industry and academia, where the synergy between industrial know-how and academic research generates tangible results in the field of advanced biofabrication.
Reproducing a biomimetic trachea scaffold means creating a construct that faithfully mimics the structure and mechanical behavior of the natural organ. The trachea is, in fact, a complex organ composed of mucosa, muscle, and cartilage, which work together to maintain airway patency and allow the passage of air.
Until now, the possibility of repairing or replacing damaged tracheal segments has been hindered by three main factors: the risk of graft rejection, the difficulty of achieving proper vascularization, and the anatomical complexity unique to each patient.
The research conducted with Electrospider aims to overcome these obstacles, paving the way for personalized solutions to medium-sized tracheal defects, such as those resulting from prolonged intubations, trauma, or congenital malformations.
Thanks to its unique ability to combine multiple biofabrication techniques within a single bioprinting session, the system enables the biofabrication of three-dimensional structures that reproduce the natural organization of tissues and their mechanical behavior.
In the specific case of the trachea, Electrospider integrates three bioprinting technologies: electrospinning, for the production of micro- and nanofibers that mimic the extracellular matrix; the Pneumatic Melt Extruder (PME), which allows the deposition of thermoplastic polymers providing mechanical stability and shape to the scaffold; and the Photocuring Pneumatic Extruder (PPE), which enables the controlled deposition of photosensitive materials—such as specific hydrogels.
“Electrospider is one of the most ambitious technological challenges we have undertaken,” said Roberto Rizzo, President and CEO of SolidWorld Group. ““The biomimetic tracheal patch we have created demonstrates the maturity of our platform and the Group’s ability to connect industrial vision with advanced research. It is a concrete step toward next-generation bioprinting, uniting science, engineering, and social impact.”
The innovative character of the platform lies in its multi-function printing head, capable of combining up to five different printing technologies within the same biofabrication session.
This enables the processing of different materials at resolutions ranging from the millimeter to the nanometer scale, and, in perspective, the development of patches and complex organs fabricated in a single process, while ensuring high repeatability, quality, and productivity.
Once the process is fully optimized, the patch can be replicated on a large scale, with minimal variation between production samples and significantly reduced fabrication time.
The project originates from the PhD research of Alessandro Velletri, carried out at the University of Pisa and co-funded by Bio3DPrinting within the framework of PNRR programs dedicated to research and innovation in the biomedical field.
Presented at the European Society for Biofabrication (ESB) Congress and at the Biofabrication 2025 Conference in Poland, it represents a significant milestone in Bio3DPrinting’s research and development path and confirms the concrete potential of the Electrospider technology.
The ability to bioprint physiologically relevant scaffolds opens new scenarios not only for in-vitro experimentation, but also paves the way for the future bioprinting of transplantable organs. The ultimate goal remains to contribute to the creation of increasingly realistic living models, capable of bridging the gap between scientific research and personalized transplantation.
“This study marks a turning point in our journey,” added Aurora De Acutis, co-founder of Bio3DPrinting. ““With Electrospider, we have demonstrated that the synergistic combination of multiple bioprinting techniques sets the stage for the biofabrication of complex constructs capable of supporting the regeneration of organ portions, such as the trachea. Our goal remains to one day bioprint transplantable organs, but this first achievement already confirms the real and measurable potential of our technology.” .”
With its biomedical division, SolidWorld Group reaffirms its long-term vision: to build an Italian 3D bioprinting supply chain capable of competing internationally and bringing additive technologies to serve regenerative medicine.
***
SolidWorld Group S.p.A. listed on Euronext Growth Milan (ticker: S3D), is an Italian technology group leader in the integration of advanced 3D digital solutions and artificial intelligence, serving strategic and next-generation industrial sectors. Founded in the early 2000s by engineer Roberto Rizzo, the Group drives the transformation of manufacturing companies toward “Factory 5.0” through proprietary software and hardware technologies that make production processes faster, more sustainable, and more efficient. Comprising 10 companies, 14 locations 3 tech hubs, and over 178 employees SolidWorld serves more than 10,000 clients. Key innovations include Electrospider, a 3D bioprinter capable of replicating human tissues and organs. As of December 31, 2024, the Group recorded a Value of Production equal to Eur 66,2 million and an EBITDA of Eur 6.5 million. www.solidworldgroup.it
CONTACTS
Investor Relations Manager
Elisabetta Cammarata
investor@solidworld.it
IR & Media Relations Advisor
Image Building Società Benefit
solidworld@imagebuilding.it – Tel. +39 02 89011300
Euronext Growth Advisor & Specialist
Integrae SIM | info@integraesim.it | T: 02 80 50 61 60 | Piazza Castello, 24 Milano
